CN103356643B - The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation - Google Patents
The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation Download PDFInfo
- Publication number
- CN103356643B CN103356643B CN201310278073.2A CN201310278073A CN103356643B CN 103356643 B CN103356643 B CN 103356643B CN 201310278073 A CN201310278073 A CN 201310278073A CN 103356643 B CN103356643 B CN 103356643B
- Authority
- CN
- China
- Prior art keywords
- chukrasonea
- chukrasone
- inflammation
- swelling
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title claims description 4
- HZUBWSRMDOJYPS-WPCVKUBSSA-N chukrasone A Natural products C=1([C@@H]2OC(=O)C[C@H]3[C@@]4(O)[C@H](O)C(=O)[C@@]5(O)[C@@H](OC(=O)C(C)C)C(C)(C)[C@@H]([C@]5([C@H]4[C@H](OC(C)=O)C[C@]32C)C)CC(=O)OC)C=COC=1 HZUBWSRMDOJYPS-WPCVKUBSSA-N 0.000 title description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 8
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 229930187319 chukrasone Natural products 0.000 abstract 3
- 230000008961 swelling Effects 0.000 description 19
- 241000700159 Rattus Species 0.000 description 13
- 210000002683 foot Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 238000003304 gavage Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Do you the present invention relates to Chukrasone? A is preparing the application in anti-inflammatory drug, does is described inflammation aseptic inflammation, described Chukrasone? A has good antiinflammatory, antiinflammation.The Chukrasone that the present invention relates to? A belongs to first public preparing the purposes in anti-inflammatory drug, because framework types belongs to brand-new framework types, and its inhibit activities for inflammation is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for antiinflammatory, obviously there is significant progress simultaneously.
Description
Technical field
The present invention relates to ChukrasoneA and prepare the application in anti-inflammatory drug.
Background technology
Inflammation occurs in local, also can affect whole body simultaneously.Local clinical feature be red, hot, swollen, pain and dysfunction.Red, heat is caused by inflammation local vascular dilation, blood flow are accelerated.Swollen is because local inflammation is congested, flow components oozes out and causes.The medicine that research and development have an antiinflammatory action for alleviation checking, palliate the agonizing sufferings significant.
The Compound C hukrasoneA that the present invention relates to is one and delivers (Liu in 2012, H.B.etal., 2012.ChukrasonesAandB:PotentialKv1.2PotassiumChannelBloc kerswithNewSkeletonsfromChukrasiatabularis.OrganicLetter s14 (17), 4438 – 4441.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to potassium-channel inhibit activities (Liu, H.B.etal., 2012.ChukrasonesAandB:PotentialKv1.2PotassiumChannelBloc kerswithNewSkeletonsfromChukrasiatabularis.OrganicLetter s14 (17), 4438 – 4441.), the ChukrasoneA that the present invention relates to is belonged to first public preparing the purposes in anti-inflammatory drug, because framework types belongs to brand-new framework types, and its inhibit activities for inflammation is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for antiinflammatory, obviously there is significant progress simultaneously.
Summary of the invention
The object of this invention is to provide ChukrasoneA and prepare the application in anti-inflammatory drug.
Described inflammation is aseptic inflammation.
Described Compound C hukrasoneA structure is as shown in formula I:
ChukrasoneA is to prepare the beneficial effect applied in anti-inflammatory drug as follows:
First demonstrate ChukrasoneA and there is effective antiinflammatory effect.Have employed the classical mice ear model caused by dimethylbenzene and rat agar foot swelling model, observe the ChukrasoneA of various dose within a certain period of time to the antiinflammatory action of laboratory animal.Research shows:
1, the mice ear caused by ChukrasoneA xylol has obvious inhibitory action, and the suppression ratio of ChukrasoneA to swelling is obvious dose-dependence, and inhibitory action increases with the increase of dosage.
2, ChukrasoneA has obvious inhibitory action to the foot swelling of rat agar.
The ChukrasoneA that the present invention relates to belongs to first public preparing the purposes in anti-inflammatory drug, because framework types belongs to brand-new framework types, and its inhibit activities for inflammation is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for antiinflammatory, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of Compound C hukrasoneA involved in the present invention is see document (Liu, H.B.etal., 2012.ChukrasonesAandB:PotentialKv1.2PotassiumChannelBloc kerswithNewSkeletonsfromChukrasiatabularis.OrganicLetter s14 (17), 4438 – 4441.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of Compound C hukrasoneA tablet involved in the present invention:
Get 20 g of compound ChukrasoneA, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of Compound C hukrasoneA capsule involved in the present invention:
Get 20 g of compound ChukrasoneA, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Test example 1:ChukrasoneA antiinflammatory pharmacodynamic study
Test material
1. Kunming (KM) plants mice: male, 6 weeks, and 18.5-22.5g is provided by Jiangsu Province's Experimental Animal Center.
2. rat (Wistar): male, weight 140 ~ 160g, is provided by Jiangsu Province's Experimental Animal Center.
Test method
1. gavage ChukrasoneA is to the effect of mouse ear inflammation: get weight 18.5 ~ 22.5g healthy male mice 50, be divided into 5 groups at random, often organizes 10.ChukrasoneA is little, in, heavy dose of group of (1.0,2.5,6.25mgkg
-1), aspirin group (200mgkg
-1), blank group (normal saline).Gastric infusion respectively, continuous 7d, 1h after the 7th day gavage, 5 groups of mices are all evenly coated with dimethylbenzene 0.02mL forward and backward of mouse right ear, prepare auricle inflammatory model.After 1h, mice is put to death in collare dislocation, cuts two ears, lay round auricle respectively, weigh and be accurate to 0.0001g with diameter 8mm card punch at the same position of two ears along auricle baseline.Another name quality is divided immediately with electronic balance, of poor quality as swelling using left and right two ear, and calculate its swelling and suppression ratio.
Swelling=auris dextra sheet weight-left auricle weight
Suppression ratio=(the average swelling of matched group-average swelling of administration group) average swelling * 100% of/matched group
1. gavage ChukrasoneA is to the effect of rat agar foot swelling: get the healthy male Wistar rat 40 of weight 140 ~ 160g, be divided into 5 groups at random.ChukrasoneA is little, in, heavy dose of group of (1.0,2.5,6.25mgkg
-1), aspirin group (200mgkg
-1), blank group (normal saline).Respectively gastric infusion, continuous 7d, 1h after the 7th day gavage, the right back foot of the rat subcutaneous injection 10g/L agar 0.1mL that wastes time prepares the swollen acute inflammation model of foot, surveys its right back sufficient normal volume with rat foot cubic content measurement instrument.Cause scorching after 1,3,5,8,24h measures the right back sufficient volume of each Mus respectively, and calculates swelling.
Result of the test
1, ChukrasoneA topical is on the impact of mouse ear inflammation
After causing inflammation, there is highly red and swollen phenomenon in each group mouse right ear at once.Aspirin group and the mice ear caused by ChukrasoneA group xylol all have obvious inhibitory action, and the suppression ratio of ChukrasoneA to swelling is obvious dose-dependence, and inhibitory action increases with the increase of dosage, the results are shown in Table 1.
The impact (x ± s) of table 1ChukrasoneA xylol induced mice auricle edema
* P<0.001 is compared, * * P<0.001 with model group
2, ChukrasoneA topical is on the impact of rat agar to foot swelling
After injection agar, each group rat foot claw all has tissue phenomenon to a certain degree.Under perusal, model group swelling is rubescent the most obvious, and slightly swelling is without obvious redness phenomenon for aspirin group, and ChukrasoneA group situation is between therebetween.Rat foot claw thickness all peaks when 3h, all slowly declines after 3h.Prolongation in time, each group of rat group turns swelling and is all diminishing, the swelling inhibitory action of aspirin group is the strongest, ChukrasoneA all has inhibitory action (p<0.05) to swollen 1,3, the 5 hour inflammation of rat foot, within 8 hours and 24 hours, compare zero difference with model group, in table 2.
Table 2ChukrasoneA is on the impact (x ± s) of rat agar toes swelling
* P<0.001 is compared, * * P<0.001 with model group
Conclusion: the mice ear caused by ChukrasoneA xylol has obvious inhibitory action; ChukrasoneA has obvious inhibitory action to the foot swelling of rat agar.ChukrasoneA may be used for preparing anti-inflammatory drug.
Claims (1)
1.ChukrasoneA preparation anti-aseptic inflammation medicine in application, described Compound C hukrasoneA structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310278073.2A CN103356643B (en) | 2013-07-04 | 2013-07-04 | The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310278073.2A CN103356643B (en) | 2013-07-04 | 2013-07-04 | The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356643A CN103356643A (en) | 2013-10-23 |
| CN103356643B true CN103356643B (en) | 2015-12-02 |
Family
ID=49359459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310278073.2A Active CN103356643B (en) | 2013-07-04 | 2013-07-04 | The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356643B (en) |
-
2013
- 2013-07-04 CN CN201310278073.2A patent/CN103356643B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Chukrasones A and B: Potential Kv1.2 Potassium Channel Blockers with New Skeletons from Chukrasia tabularis;Hong-Bing Liu et. al.;《Organic Letters》;20120810;第14卷(第17期);第4438-4441页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356643A (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103356643B (en) | The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation | |
| CN103356594B (en) | The application of Chukrasone B in the anti-aseptic inflammation medicine of preparation | |
| CN105412065A (en) | Application of Mycoleptodiscin A in preparing aseptic inflammation resisting medicine | |
| CN103340874B (en) | The application of Myriberine A in the anti-aseptic inflammation medicine of preparation | |
| CN103393673B (en) | Application of compound in anti-aseptic inflammation drug preparation | |
| CN103251859B (en) | One treats dermopathic pharmaceutical composition | |
| CN105287602A (en) | Application of Trigonoliimine A in preparation of aseptic inflammation resisting medicine | |
| CN105434419A (en) | Use of Altertoxin IV in preparation of aseptic inflammation-diminishing drug | |
| CN105412098A (en) | Application of Melodinine E in preparing drugs for anti-aseptic inflammation | |
| CN102988379B (en) | Application of Houttuynoid C for preparing aseptic inflammation resistant medicine | |
| CN103127075A (en) | Application of Aphanamixoid A to aseptic inflammation resistance medicine | |
| CN103203000A (en) | Ointment for treatment of keloid | |
| CN102872037B (en) | Application of Gypensapogenin B in preparing medicaments against aseptic inflammation | |
| CN103263545B (en) | Traditional Chinese medicine for treating seborrheic dermatitis | |
| CN106265639A (en) | Linderolide H application in preparation anti-bacteria-free inflammation | |
| CN106361747A (en) | Application of Ternatusine A in preparation of drugs for resisting aseptic inflammations | |
| CN103393664A (en) | Application of Sarcaboside A to medicament for resisting aseptic inflammation | |
| CN103356537A (en) | Application of Sarcaboside B in preparation of medicines for resisting aseptic inflammation | |
| CN103251625A (en) | Application of Aspeverin in preparation of anti-bacteria-free inflammation medicines | |
| CN103120658A (en) | Application of Eryngiolide A in medicine for resisting aseptic inflammation | |
| CN103127154A (en) | Application of Gypensapogenin A in medicines resisting aseptic inflammation | |
| CN102988389A (en) | Application of Houttuynoid B for preparing aseptic inflammation resistant medicine | |
| CN109420101A (en) | A kind of drug of systemic lupus erythematosus | |
| CN107865858A (en) | Applications of the Apigenin in anti-bacteria-free inflammation is prepared | |
| CN107865882A (en) | Applications of the Orientin in anti-bacteria-free inflammation is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| GR01 | Patent grant | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151109 Address after: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Applicant after: Gu Xiangmao Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Applicant before: Ding Shengyu |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Huo Na Inventor after: Diao Xiangyou Inventor after: Yu Sanping Inventor before: Ding Shengyu |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170407 Address after: 071051 Baoding City, the new city of Victory Lane, Lane 2, building 3, unit 302, No., No. 69 Patentee after: Huo Na Patentee after: Diao Xiangyou Patentee after: Yu Sanping Address before: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Patentee before: Gu Xiangmao |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181228 Address after: Room 107, Di Shang Science and Technology House, West District, Chang Xincun, Jizhou District, Tianjin 301900 Patentee after: Tianjin ocean Hangzhou Science and Technology Co.,Ltd. Address before: 071051 Shengli Lane, 69 Gates, 2 Buildings, 3 Units 302, Baoding New City, Hebei Province Co-patentee before: Diao Xiangyou Patentee before: Huo Na Co-patentee before: Yu Sanping |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190617 Address after: 300 000 No. 1 and No. 2, Row 1, West Xinghuali Section, Yuyang Town, Jizhou District, Tianjin Patentee after: Century Taihe Hospital, Jizhou District, Tianjin Address before: Room 107, Di Shang Science and Technology House, West District, Chang Xincun, Jizhou District, Tianjin 301900 Patentee before: Tianjin ocean Hangzhou Science and Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191008 Address after: 233000 Xianghe Home Floor No.9, Xinhuai Road, Dongsheng Street, Longzihu District, Bengbu City, Anhui Province Patentee after: Bengbu Qibang Science and Technology Information Consulting Co.,Ltd. Address before: 300 000 No. 1 and No. 2, Row 1, West Xinghuali Section, Yuyang Town, Jizhou District, Tianjin Patentee before: Century Taihe Hospital, Jizhou District, Tianjin |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231009 Address after: Room 401, Dongjun Huacheng Plaza, No. 166, Section 1, Wanjiali Middle Road, Hehuayuan Street, Furong District, Changsha City, Hunan Province, 410000 Patentee after: Hunan Zhuoyantang Biotechnology Co.,Ltd. Address before: 233000 No.9, 1st floor, Xianghe Jiayuan, Xinhuai Road, Dongsheng Street, Longzihu District, Bengbu City, Anhui Province Patentee before: Bengbu Qibang Science and Technology Information Consulting Co.,Ltd. |